Literature DB >> 15664155

Lyn tyrosine kinase: accentuating the positive and the negative.

Yuekang Xu1, Kenneth W Harder, Nicholas D Huntington, Margaret L Hibbs, David M Tarlinton.   

Abstract

Lyn, one of several Src-family tyrosine kinases in immune cells, is noted for its ability to negatively regulate signaling pathways through phosphorylation of inhibitory receptors, enzymes, and adaptors. Somewhat paradoxically, it is also a key mediator in several pathways of B cell activation, such as CD19 and CD180. Whether Lyn functions to promote or inhibit immune cell activation depends on the stimulus and the developmental state, meaning that the consequences of Lyn activity are context dependent. The importance of regulating Lyn activity is exemplified by the pathological conditions that develop in both lyn-/- and lyn gain-of-function mice (lynup/up), including lethal antibody-mediated autoimmune diseases and myeloid neoplasia. Here, we review the outcomes of altered Lyn activity within the framework of B cell development and differentiation and the circumstances that appear to dictate the outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664155     DOI: 10.1016/j.immuni.2004.12.004

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  129 in total

Review 1.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8.

Authors:  Heping Xu; Virendra K Chaudhri; Zhiguo Wu; Konstantinos Biliouris; Krista Dienger-Stambaugh; Yrina Rochman; Harinder Singh
Journal:  Nat Immunol       Date:  2015-10-05       Impact factor: 25.606

3.  Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.

Authors:  Anna Parente-Ribes; Sigrid S Skånland; Simone Bürgler; Audun Os; Dong Wang; Bjarne Bogen; Geir E Tjønnfjord; Kjetil Taskén; Ludvig A Munthe
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

4.  Positive and negative regulation of mast cell activation by Lyn via the FcepsilonRI.

Authors:  Wenbin Xiao; Hajime Nishimoto; Hong Hong; Jiro Kitaura; Satoshi Nunomura; Mari Maeda-Yamamoto; Yuko Kawakami; Clifford A Lowell; Chisei Ra; Toshiaki Kawakami
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

5.  ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.

Authors:  Prabhjit K Grewal; Mark Boton; Kevin Ramirez; Brian E Collins; Akira Saito; Ryan S Green; Kazuaki Ohtsubo; Daniel Chui; Jamey D Marth
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 6.  CD45: all is not yet crystal clear.

Authors:  Nick Holmes
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

7.  The lectin Jacalin induces human B-lymphocyte apoptosis through glycosylation-dependent interaction with CD45.

Authors:  Bruce Yong Ma; Kaori Yoshida; Makoto Baba; Motohiro Nonaka; Shogo Matsumoto; Nobuko Kawasaki; Shinji Asano; Toshisuke Kawasaki
Journal:  Immunology       Date:  2008-10-30       Impact factor: 7.397

8.  LYN- and AIRE-mediated tolerance checkpoint defects synergize to trigger organ-specific autoimmunity.

Authors:  Irina Proekt; Corey N Miller; Marion Jeanne; Kayla J Fasano; James J Moon; Clifford A Lowell; Douglas B Gould; Mark S Anderson; Anthony L DeFranco
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

Review 9.  Multiple roles of Lyn kinase in myeloid cell signaling and function.

Authors:  Patrizia Scapini; Shalini Pereira; Hong Zhang; Clifford A Lowell
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

10.  A novel Lyn-protein kinase Cδ/ε-protein kinase D axis is activated in B cells by signalosome-independent alternate pathway BCR signaling.

Authors:  Benchang Guo; Thomas L Rothstein
Journal:  Eur J Immunol       Date:  2013-04-12       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.